Skip to search formSkip to main contentSkip to account menu

refametinib

An orally bioavailable selective MEK inhibitor with potential antineoplastic activity. Refametinib specifically inhibits mitogen-activated protein… 
National Institutes of Health

Related topics

Related topics

1 relation

Narrower (1)

RDEA 119

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Refametinib in RAS-mutated hepatocellular cancer.
2017
2017
Determination of Structural Requirements of N-Substituted Tetrahydro-β-Carboline Imidazolium Salt Derivatives Using in Silico Approaches for Designing MEK-1 Inhibitors
Novel N-substituted tetrahydro-β-carboline imidazolium salt derivatives proved to have potent antitumor activity in past research… 
2017
2017
Chemical-biology approach to delineate the mechanism of action of HIV-1 latency reversing agents
Prostratin exhibits potent HIV-1 latency reversing activity, yet its molecular mechanism of action has not been defined in detail… 
2017
2017
Rational combination therapy in young vs older patients with advanced colorectal cancer (CRC).
612Background: Although CRC is rare in young adults, the incidence has increased recently and patients present more commonly with… 
2016
2016
Targeted therapy in low-grade serous ovarian carcinoma : characterization of MEK inhibitor response in novel patient-derived cell lines
2015
2015
Abstract 5239: KRAS wild-type status as detected by circulating tumor DNA analysis may be a prognostic or predictive factor for clinical benefit in patients with unresectable, locally advanced or…
Background: Mutationally-activated KRAS is present in 90% of pancreatic ductal adenocarcinoma (PDAC) and may represent an early… 
2014
2014
Phase II study of the MEK inhibitor refametinib (BAY 86-9766) in combination with gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer: Biomarker results.
4129 Background: Refametinib is a potent oral allosteric MEK 1/2 inhibitor with both single-agent and synergistic activity in… 
2014
2014
First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward.
Pancreatic cancer is a lethal disease and its prognosis remains dismal. The modest results of existing available treatments in… 
2014
2014
Compositions pharmaceutiques contenant du réfamétinib
La presente invention concerne des compositions pharmaceutiques contenant du refametinib, un hydrate, un solvate, un metabolite… 
2014
2014
Cancer Therapy : Clinical APhase II Study of theEf fi cacy andSafety of theCombination Therapy of theMEK Inhibitor Refametinib ( BAY 86-9766 ) Plus Sorafenib for Asian Patients with Unresectable…
Purpose: There is an unmet need for treatment options in hepatocellular carcinoma (HCC). Sorafenib is currently the only approved… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)